Phathom Pharmaceuticals PHAT
$4.66 −$0.42 (-8.27%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.66 0.00%
Open$4.93
Prev close$5.08
Day range$4.62 – $5.15
Volume1.33M
Market cap$378.82M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±7.6%last 12 reports
Closed higher4 of 1233% of the time
Best reaction+10.1%
Worst reaction-22.4%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | Pre Market | ±51.5% | -0.96% | Within range |
| 2026/Q2 | 30 Jul 2026 | Pre Market | ±26.8% | -22.42% | Within range |
| 2026/Q1 | 30 Apr 2026 | Pre Market | ±23.9% | -4.92% | Within range |
| 2025/Q4 | 26 Feb 2026 | Pre Market | ±32.7% | +10.06% | Within range |
| 2025/Q3 | 30 Oct 2025 | Pre Market | ±30.0% | -1.63% | Within range |
| 2025/Q2 | 7 Aug 2025 | Pre Market | ±36.7% | +8.29% | Within range |
| 2025/Q1 | 1 May 2025 | None | ±34.8% | -21.68% | Within range |
| 2024/Q4 | 6 Mar 2025 | None | ±37.2% | -2.96% | Within range |
| 2024/Q3 | 7 Nov 2024 | Pre Market | ±21.9% | +2.78% | Within range |
| 2024/Q2 | 8 Aug 2024 | Pre Market | ±28.1% | +8.70% | Within range |
| 2024/Q1 | 9 May 2024 | Pre Market | ±20.0% | -0.10% | Within range |
| 2023/Q4 | 7 Mar 2024 | Pre Market | ±21.2% | -6.58% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$84.72M+71.1% YoY
Operating profit-$85,000.00+99.4% YoY
Net profit-$13.90M+53.6% YoY
Diluted EPS-$0.16+61.0% YoY
Free cash flow$1.73M+112.2% YoY
Operating cash flow$1.84M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
Return on assets-28.4%
Current ratio1.76
Liabilities / assets200.8%
Cash & investments$184.56M
Total debt$167.28M
Net cash (debt)$17.27M
No comments yet — be the first to weigh in on PHAT.
Sign in to join the discussion.